Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model
Mingjun Rui, Fenghao Shi, Ye Shang, Rui Meng, Hongchao Li
Topics & Concepts
GemcitabineMedicineOncologyCisplatinInternal medicineBreast cancerTriple-negative breast cancerPaclitaxelMetastatic breast cancerCancerChemotherapyCancer Treatment and PharmacologyEconomic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life